Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Panbela Therapeutics files $100M mixed securities shelf  16:12
05/04/21
05/04
16:12
05/04/21
16:12
PBLA

Panbela Therapeutics

$4.22 /

-0.42 (-9.05%)

 
ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.22 /

-0.42 (-9.05%)

PBLA Panbela Therapeutics
$4.22 /

-0.42 (-9.05%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PBLA Panbela Therapeutics
$4.22 /

-0.42 (-9.05%)

Over a week ago
Hot Stocks
Panbela reports partial clinical hold lifted on Phase 1 study of SBP-101 » 08:07
04/15/21
04/15
08:07
04/15/21
08:07
PBLA

Panbela Therapeutics

$4.00 /

-0.11 (-2.68%)

Panbela Therapeutics…

Panbela Therapeutics announced the U.S. Food and Drug Administration has lifted the partial clinical hold on the company's Phase 1 first-line study of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for treatment of patients with metastatic pancreatic ductal adenocarcinoma. SBP-101 is the company's first polyamine metabolic inhibitor therapeutic candidate. The company has agreed to include in the design of all future studies the exclusion of patients with a history of retinopathy or at risk of retinal detachment and scheduled ophthalmologic monitoring for all patients. Additionally, in future dose-finding studies screening for retinal toxicity will be included.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.00 /

-0.11 (-2.68%)

PBLA Panbela Therapeutics
$4.00 /

-0.11 (-2.68%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PBLA Panbela Therapeutics
$4.00 /

-0.11 (-2.68%)

Conference/Events
Panbela Therapeutics participates in a conference call with Maxim » 04:55
04/13/21
04/13
04:55
04/13/21
04:55
PBLA

Panbela Therapeutics

$4.46 /

+0.21 (+4.94%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Simpson & CFO Horvath on April 13 hosted by Maxim.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.46 /

+0.21 (+4.94%)

PBLA Panbela Therapeutics
$4.46 /

+0.21 (+4.94%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PBLA Panbela Therapeutics
$4.46 /

+0.21 (+4.94%)

Over a month ago
Conference/Events
Panbela Therapeutics participates in a conference call with Maxim » 11:23
04/06/21
04/06
11:23
04/06/21
11:23
PBLA

Panbela Therapeutics

$4.34 /

+0.2 (+4.83%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Simpson & CFO Horvath on April 13 hosted by Maxim.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.34 /

+0.2 (+4.83%)

PBLA Panbela Therapeutics
$4.34 /

+0.2 (+4.83%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PBLA Panbela Therapeutics
$4.34 /

+0.2 (+4.83%)

Earnings
Panbela Therapeutics reports Q4 EPS (9c), one est. (15c) » 08:44
03/26/21
03/26
08:44
03/26/21
08:44
PBLA

Panbela Therapeutics

$4.24 /

-0.09 (-2.08%)

"2020 was a year of…

"2020 was a year of significant accomplishments for SBP-101 and Panbela as a public company. In 2021 we are focused on continued execution of our pancreatic cancer program and expanding our addressable market opportunity outside of pancreatic cancer," said Jennifer Simpson, PhD, MSN, CRNP President & CEO of Panbela Therapeutics. "Last year's achievements included securing fast track designation for SB1-101 in 1L metastatic pancreatic cancer, completing Phase 1b trial enrollment, strengthening our leadership team, firming up our balance sheet and uplisting to Nasdaq. This year we are focused on leveraging 2020's successes to execute on upcoming SBP-101 milestones in pancreatic cancer. We are also committed to expanding our total addressable market beyond pancreatic cancer. In support of that goal, we have appointed Garry A. Weems, PharmD as VP of Clinical Development and Medical Affairs, and entered into a research agreement with the Johns Hopkins University School of Medicine. We look forward to ongoing preclinical work yielding data in the second half of the year to inform future development pathways across tumors outside of pancreatic cancer as well as the potential combination with checkpoint inhibitors."

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.24 /

-0.09 (-2.08%)

PBLA Panbela Therapeutics
$4.24 /

-0.09 (-2.08%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
Hot Stocks
Panbela Therapeutics names Garry Weems as VP of clinical development » 08:04
03/15/21
03/15
08:04
03/15/21
08:04
PBLA

Panbela Therapeutics

$4.46 /

-0.05 (-1.11%)

, CERC

Cerecor

$3.38 /

+0.08 (+2.42%)

Panbela Therapeutics,…

Panbela Therapeutics, Inc. (PBLA) announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (CERC) where he was Senior Director of Clinical Development. "Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101," said Jennifer Simpson, CEO at Panbela. "Garry's substantial background of success and extensive experience in executing clinical programs in oncology, including immunotherapy, will bring tremendous value to Panbela. With key milestones expected during this year, as well as communications with the U.S. Food and Drug Administration that will help shape our lead program in pancreatic cancer, his expertise will be an asset straightaway."

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.46 /

-0.05 (-1.11%)

CERC Cerecor
$3.38 /

+0.08 (+2.42%)

PBLA Panbela Therapeutics
$4.46 /

-0.05 (-1.11%)

03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
CERC Cerecor
$3.38 /

+0.08 (+2.42%)

  • 08
    Jan
  • 09
    Jun
CERC Cerecor
$3.38 /

+0.08 (+2.42%)

Initiation
Panbela Therapeutics initiated with a Buy at Maxim » 08:22
03/10/21
03/10
08:22
03/10/21
08:22
PBLA

Panbela Therapeutics

$4.15 /

-0.15 (-3.49%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Panbela Therapeutics with a Buy rating and $8 price target. The analyst notes that long-term patient survival in pancreatic ductal adenocarcinoma has not improved significantly since the approval of gemcitabine over 20 years ago, and he views the company's developing SBP-101 implementing a "differentiated" mechanism of action that may improve treatment outcomes when used with standard-of-care therapies.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$4.15 /

-0.15 (-3.49%)

Hot Stocks
Panbela Therapeutics enters research agreement with Johns Hopkins University » 08:32
02/10/21
02/10
08:32
02/10/21
08:32
PBLA

Panbela Therapeutics

$8.19 /

+0.08 (+0.99%)

Panbela Therapeutics…

Panbela Therapeutics announced a research agreement with the Johns Hopkins University School of Medicine. The collaboration is intended to focus on the further development of Panbela's investigative agent SBP-101, including activity in cell lines outside of pancreatic cancer, biomarkers informing diagnostics and potential combination with checkpoint inhibitors. The research will be led by Prof. Robert Casero, an internationally recognized researcher in polyamine biology at the Johns Hopkins Kimmel Cancer Center and a professor of oncology at Johns Hopkins University School of Medicine. Prof. Casero is a molecular pharmacologist whose research focuses on developing drugs that target critical pathways for chemotherapy and chemoprevention, including amine metabolism, epigenetic regulation and inflammation.

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$8.19 /

+0.08 (+0.99%)

Hot Stocks
Panbela Therapeutics Inc trading resumes  08:30
02/10/21
02/10
08:30
02/10/21
08:30
PBLA

Panbela Therapeutics

$8.19 /

+0.08 (+0.99%)

 
ShowHide Related Items >><<
PBLA Panbela Therapeutics
$8.19 /

+0.08 (+0.99%)

Hot Stocks
Panbela Therapeutics says DSMB recommends hold on SBP-101 administration » 08:05
02/10/21
02/10
08:05
02/10/21
08:05
PBLA

Panbela Therapeutics

$8.19 /

+0.08 (+0.99%)

Panbela Therapeutics has…

Panbela Therapeutics has been evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma. SBP-101 has received Fast Track and Orphan Drug designation from FDA and Panbela has been working closely with the FDA to advance its development studies of SBP-101 for patients with metastatic PDA. The company said, "Panbela continues to be in communication with the trial investigators regarding the recommendation from the independent data safety monitoring board of the ongoing Phase 1 clinical trial to hold administration of SBP-101 pending further investigation of visual disturbance adverse events. Some patients in the trial were noted to have complaints of visual changes, although visual changes were not seen in the SBP-101 monotherapy study. We have consulted with the DSMB and SBP-101 will not be administered to ongoing patients in the current trial while additional safety information is analyzed. Patients will continue with the standard drug regimen. All other trial activities continue. Panbela has conferred with FDA regarding the plan to continue the trial but hold dosing of SBP-101 in ongoing patients until we can learn more. Withholding SBP-101 constitutes a "partial clinical hold". There is no impact on enrollment, as enrollment of the trial completed in December 2020, and the study is ongoing. Panbela is working to finalize a visual screening program in order to understand the significance of reported visual changes and to inform future studies. We will also seek to evaluate the exact cause of these recent visual reports and to determine whether serial eye exams during treatment can identify potential toxicity or risk before symptoms develop. While we evaluate supplementary data, we remain confident in the potential benefits of SBP-101 including its potential benefits for patients with pancreatic cancer. We are thankful to the patients who have, or are, participating in our clinical trials. We are committed to objectively evaluating the data from those clinical studies to confirm both the therapeutic benefits and safety profile of our polyamine inhibitor in metastatic pancreatic cancer patients. Panbela is planning to submit interim results at a major cancer conference and looks forward to publication of final efficacy and safety data, when available. Additionally, all other research and manufacturing activities related to future SBP-101 indications are continuing, including working with the FDA to initiate a randomized trial mid-year."

ShowHide Related Items >><<
PBLA Panbela Therapeutics
$8.19 /

+0.08 (+0.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.